Evidence map›Paper›PMID 35943588›Full record

ReviewAnnals of hematology2022

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes.

Xavier Leleu, Thomas Martin, Katja Weisel, Fredrik Schjesvold, Shinsuke Iida, Fabio Malavasi, Salomon Manier, Chang-Ki Min, Enrique M Ocio, Charlotte Pawlyn and 6 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. CD8Blood neoplasia · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 11 countries.

Xavier LeleuService d'Hématologie Et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers Cedex, France. Xavier.LELEU@chu-poitiers.fr.
Thomas MartinDepartment of Medicine, University of California at San Francisco, San Francisco, CA, USA.
Katja WeiselUniversity Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Fredrik SchjesvoldOslo Myeloma Center, Department of Hematology, KG Jebsen Center for B Cell Malignancies, Oslo University Hospital, University of Oslo, Oslo, Norway.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University, Nagoya, Japan.
Fabio MalavasiDepartment of Medical Sciences, University of Torino Medical School, Fondazione Ricerca Molinette, Turin, Italy.
Salomon ManierDepartment of Hematology, CHU, Universite de Lille, Lille, France.
Chang-Ki MinDepartment of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Enrique M OcioHospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
Charlotte PawlynDivision of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
Aurore PerrotDepartment of Hematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
Hang QuachClinical Haematology Service, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.
Joshua RichterDivision of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai, New York, NY, USA.
Ivan SpickaDepartment of Medicine, Department of Hematology, First Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
Kwee YongDepartment of Haematology, University College, Hospitals NHS Foundation Trust, London, UK.
Paul G RichardsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Charles University · CZDana-Farber Cancer Institute · USFondazione Ricerca Molinette · ITInserm · FRInstitute of Cancer Research · GBMarqués de Valdecilla University Hospital · ESNagoya City University · JPSeoul St. Mary's Hospital · KRSt Vincent's Hospital · AUTisch Hospital · USUniversität Hamburg · DEUniversité de Lille · FRUniversity College London Hospitals NHS Foundation Trust · GBUniversity of California, San Francisco · USUniversity of Oslo · NO

Funding

Cancer Research UK 29957
6 · The paper itself

Abstract

CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High expression on multiple myeloma (MM) cells and limited expression on normal cells makes CD38 an ideal target for the treatment of MM patients. Two monoclonal antibodies directed at CD38, isatuximab and daratumumab, are available for use in patients with relapsed and/or refractory MM (RRMM); daratumumab is also approved in newly diagnosed MM and light-chain amyloidosis. Clinical experience has shown that anti-CD38 antibody therapy is transforming treatment of MM owing to its anti-myeloma efficacy and manageable safety profile. Isatuximab and daratumumab possess similarities and differences in their mechanisms of action, likely imparted by their binding to distinct, non-overlapping epitopes on the CD38 molecule. In this review, we present the mechanistic properties of these two antibodies and outline available evidence on their abilities to induce adaptive immune responses and modulate the bone marrow niche in MM. Further, we discuss differences in regulatory labeling between these two agents and analyze recent key clinical trial results, including evidence in patients with underlying renal impairment and other poor prognostic factors. Finally, we describe the limited existing evidence for the use of isatuximab or daratumumab after disease progression on prior anti-CD38 mono- or combination therapy, highlighting the need for additional clinical evaluations to define optimal anti-CD38 antibody therapy selection and sequencing in RRMM.

Indexed as

Antineoplastic Agents, ImmunologicalMultiple MyelomaADP-ribosyl Cyclase 1Clinical Trials as TopicHumansTumor MicroenvironmentADP-ribosyl Cyclase 1Antineoplastic Agents, ImmunologicalCD38Monoclonal antibodyMyelomaTherapy

Identifiers

PMID35943588
PMCPMC9463192
OpenAlexW4292451915

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.